<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192828</url>
  </required_header>
  <id_info>
    <org_study_id>08-1376</org_study_id>
    <secondary_id>FDR003907</secondary_id>
    <nct_id>NCT01192828</nct_id>
  </id_info>
  <brief_title>Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine</brief_title>
  <official_title>Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystathionine beta-synthase deficiency is an inherited disease that results in elevation of a
      substance called homocysteine (Hcy) in blood and urine. Individuals with this disorder have a
      very high risk for developing blood clots and are at risk for developing eye and bone
      abnormalities. Current treatments are generally difficult to follow and can fail. Development
      of additional therapies has been limited by lack of understanding of how the disease works.

      The purpose of this study is to see if oxidative stress and inflammation are involved in the
      disease process and if short-term supplementation with taurine is an effective treatment.

      Funding source: FDA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystathionine beta-synthase deficient homocystinuria(CBSDH) is an inherited disease that
      results in elevation of a substance called homocysteine(Hcy)in blood and urine. Individuals
      with this disorder have a very high risk for developing blood clots that can cause a stroke
      or other life-threatening problems. In addition, these individuals have bone and joint tissue
      abnormalities.

      Current treatment with an extremely strict diet and medication (betaine) is very difficult to
      follow, and often fails. Development of additional treatment strategies has been limited by a
      lack of knowledge and understanding of how this disease works. Hence, there is a need to
      better understand what causes the blood clots and the bone and joint tissue abnormalities.

      New data suggest that oxidative stress and inflammation play a central role in animals with
      this disease. Limited data on humans with this disease support this as well. Further, data
      from animals with this disease suggests that taurine, a natural body substance and food
      product, which is low in these patients, mitigates this effect. This study is designed to
      follow-up on these data.

      The purpose of the study is to increase our understanding of the disease process in this
      disorder, and to see in a pilot study if short-term supplementation with taurine is an
      effective intervention. The aims of the study are to:

        1. see if substances (markers) associated with oxidative stress and inflammation are
           increased in individuals with CBSDH

        2. see if the levels of these markers relate to the levels of homocysteine

        3. see if the levels of these markers decrease with short-term taurine supplementation

        4. see how bood vessels and platelets (small substances in the blood that help blood clot)
           work in individuals with CBSDH, if their ability to work is related to levels of markers
           of oxidative stress and inflammation, and if taurine supplementation improves how they
           work

        5. see if alterations of bone strength are related to levels of markers of inflammation.

      The hypotheses to be investigated are as follows:

        -  Biomarkers of oxidative stress and inflammation are increased in individuals with CBSDH

        -  The degree of elevation of the biomarkers of oxidative stress and inflammation is
           relative to the degree of elevation of homocysteine, the main accumulating substance for
           this disease.

        -  Treatment with taurine mitigates the elevation of biomarkers of oxidative stress and
           inflammation.

        -  Endothelial function (blood vessel function) is abnormal in individuals with CBSDH even
           when receiving standard therapy and is improved with taurine supplementation.

        -  Chronic platelet aggregation, a variable finding in individuals with CBSDH, is mitigated
           with taurine supplementation.

        -  Decreased bone mineral density relates to the increase in inflammatory markers in CBSDH.

      In addition, baseline pharmacokinetics (how much taurine is in the blood) of oral
      pharmacologic doses of taurine will be developed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine Treatment.</measure>
    <time_frame>Baseline and after 4 days of therapy.</time_frame>
    <description>TBARS were measured in plasma via colorimetric absorbance. TBARS are a marker of oxidative stress. They are formed as a by-product of lipid (fat) oxidation. TBARS predominantly reflect the level of malondialdehyde (MDA) a substance that is formed from the breakdown of polyunsaturated fatty acids.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Tumor Necrosis Factor Alpha (TNF-alpha) in Individuals With CBSDH Pre and Post Taurine Treatment.</measure>
    <time_frame>Baseline and after 4 days of treatment.</time_frame>
    <description>TNF-alpha was measured in plasma via Luminex high sensitivity assay. TNF-alpha is a signaling protein, or cytokine that promotes an inflammatory response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH Pre and Post Taurine Treatment</measure>
    <time_frame>Baseline and after 4.5 days of taurine treatment</time_frame>
    <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH and Homocysteine Levels Greater Than 125 Micromole/L Pre and Post Taurine Treatment.</measure>
    <time_frame>Baseline and after 4.5 days of therapy.</time_frame>
    <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH and Pre Taurine Exposure FMD Values Less Than 10 mm Pre and Post Taurine Treatment.</measure>
    <time_frame>Baseline and after 4.5 days of therapy.</time_frame>
    <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Individuals With Decreased Bone Mineral Density.</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone mineral density was assessed via whole body dual energy X-ray absorptiometry (DEXA) with bone density corrected for age. The absolute DEXA value was not used for analysis, rather values below 2 standard deviations of normal were taken as evidence of osteoporosis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With CBSDH Compare to Homocysteine Level.</measure>
    <time_frame>Baseline</time_frame>
    <description>TBARS were measured in plasma via colorimetric absorbance. Homocysteine was measured in serum by gas chromatography/mass spectrometry (GC/MS) in a Clinical Laboratory Improvements Amendments (CLIA) approved clinical laboratory. TBARS are a marker of oxidative stress. TBARS are formed as a by-product of lipid (fat) oxidation. TBARS predominantly reflect the level of malondialdehyde (MDA) a substance that is formed from the breakdown of polyunsaturated fatty acids.</description>
  </other_outcome>
  <other_outcome>
    <measure>Determination of Baseline Taurine Level, Peak Taurine Level on Day One, Trough Level on Day One and Trough Level on Day Four of Taurine Treatment.</measure>
    <time_frame>Taurine levels were obtained prior to taurine adminstration and at , t=0.5, t=1, t=2, t=3, t=4, t=6, t=8, t=12 and 96 hours.</time_frame>
    <description>Taurine was measured in plasma via liquid chromatogram(LC)-MS/MS.</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in Triglycerides in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment)</measure>
    <time_frame>Baseline and after 4 days of treatment.</time_frame>
    <description>Triglycerides were measured in a CLIA approved clinical laboratory.Triglycerides are a natural occurring fat. High levels over a long period of time can increase the chances for heart disease. Levels greater that 1000 mg/dl over a short period of time can increase chances of pancreatitis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in Triglycerides in Individuals With CBSDH Receiving Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment)</measure>
    <time_frame>Baseline and after 4 days of treatment.</time_frame>
    <description>Triglycerides were measured in a CLIA approved clinical laboratory. Triglycerides are a natural occurring fat, High levels over a long period of time can increase the chances for heart disease. Levels greater that 1000 mg/dl over a short period of time can increase chances of pancreatitis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Difference in Systolic Blood Pressure in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment).</measure>
    <time_frame>Baseline and after 4 days of treatment.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Difference in Diastolic Blood Pressure in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment).</measure>
    <time_frame>Baseline and after 4 days of treatment.</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Homocystinuria</condition>
  <arm_group>
    <arm_group_label>Taurine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Taurine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>taurine</intervention_name>
    <description>Take Taurine for 4 1/2 days, two doses per day</description>
    <arm_group_label>Taurine</arm_group_label>
    <other_name>Not Applicable. No other names.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A confirmed biochemical, molecular, or enzymatic diagnosis of classic homocystinuria
             due to cystathionine beta-synthase deficiency (OMIM 236200)

          2. And not fully responsive to therapy (eg, total homocysteine (tHcy) levels above 50
             Âµmol/L on therapy including on B6 therapy)

          3. Be over 8 years old and less than 50 years. The first four patients will be adults
             (age 18-50 years)

          4. Be able and willing to provide informed consent

        Exclusion Criteria:

          1. Pregnancy: Females who are pregnant or lactating will be excluded from the study as
             the influence of pregnancy on the markers is not known nor is the safety of taurine
             supplementation in pregnancy.

          2. Continued antioxidant intake:

               1. Individuals currently taking taurine, over the counter energy drinks containing
                  taurine or other high dose antioxidants and unwilling to discontinue this for the
                  study period (including a 2 week wash out period) will be excluded as such intake
                  will likely impact laboratory results.

               2. Individuals taking Vitamin C as a prescribed treatment for their homocystinuria
                  will be excluded as the antioxidant therapy may impact antioxidant and
                  inflammation markers. (As Vitamin C is not standard of care for this disease we
                  anticipate this to have minimal impact on recruitment.)

               3. Individuals currently taking platelet aggregation inhibitors such as salicylate
                  on a self prescribed basis and unwilling to discontinue this for the study period
                  (including a washout period of at least two weeks prior to the study) will be
                  excluded as salicylate intake will impact platelet study results. Individuals
                  taking salicylate (or other platelet aggregation inhibitors) prescribed as a
                  therapy for their homocystinuria or other health issues will not be asked to stop
                  the medication. They will participate in the study, but will be excluded only
                  from the platelet studies.

          3. Medication interactions: Individuals unable or unwilling to abstain from use of cyclic
             guanosine monophosphate (cGMP) phosphodiesterase 5 inhibitors (such as Viagra) during
             the study period will be excluded from the nitroglycerin-induced flow-mediated
             dilatation studies in accordance with known labeling contraindications.

          4. Inflammatory status:

               1. Individuals who have a significant chronic illness that has a marked inflammatory
                  component will be excluded from the study as the illness will impact inflammatory
                  markers.

               2. Patients with an acute illness, which may impact inflammatory biomarkers, will be
                  postponed for study entry until the acute illness is resolved. Entry into the
                  study at a later day will be offered.

          5. Recent cardiovascular event. Cardiovascular events (stroke, myocardial infarct, deep
             vein thrombosis, pulmonary embolus, thrombosis, or uncontrolled hypertension) may
             interfere with platelet function studies and with various mediators during the first
             months after the event. Patients who had such an event within the last 6 months will
             be excluded.

          6. Hypertriglyceridemia. Individuals with a triglyceride level above 300 mg/dl will be
             excluded from the study.

          7. Informed consent: Individuals who are unwilling or unable to consent, or in the case
             of minors who are unwilling or unable to assent will be excluded due to lack of
             ability to ensure informed consent.

          8. Study compliance and integrity: Individual who anticipate an inability to comply with
             study procedures and requirements will be excluded.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan VanHove, MD PhD MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>April 26, 2018</results_first_submitted>
  <results_first_submitted_qc>June 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2018</results_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cystathionine beta-synthase (CBS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Homocystinuria</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01192828/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and recruited from three sites in the United States.</recruitment_details>
      <pre_assignment_details>After enrollment a washout period for medications was required. At first study visit, assignment to arm occurred. One individual, while consented, did not participate at first study visit due to acute illness, was never rescheduled, and was removed. Number of subjects who started arm and completed study was thus 14.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Taurine Intervention</title>
          <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). The next subjects received target high dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Taurine Intervention</title>
          <description>Treatment with taurine for 4 1/2 days, two doses per day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>Total number of participant enrolled in study was 15. One subject who enrolled per phone had to postpone study visit due to acute illness. This individual failed to reschedule for study visit and was eventually removed from the study. Number of subjects who completed study and analyzed is therefore 14.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age Distribution by Meaningful Groups</title>
              <category_list>
                <category>
                  <title>Prepubertal (8-12 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Teenagers (12-&lt;20 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Young Adults (20-&lt;30 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Older Adults (30-50 years)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Total number of participant enrolled in study was 15. One subject who enrolled per phone had to postpone study visit due to acute illness. This individual failed to reschedule for study visit and was eventually removed from the study. Number of subjects who completed study and analyzed is therefore 14.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Total number of participant enrolled in study was 15. One subject who enrolled per phone had to postpone study visit due to acute illness. This individual failed to reschedule for study visit and was eventually removed from the study. Number of subjects who completed study and analyzed is therefore 14</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Categories</title>
              <category_list>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine Treatment.</title>
        <description>TBARS were measured in plasma via colorimetric absorbance. TBARS are a marker of oxidative stress. They are formed as a by-product of lipid (fat) oxidation. TBARS predominantly reflect the level of malondialdehyde (MDA) a substance that is formed from the breakdown of polyunsaturated fatty acids.</description>
        <time_frame>Baseline and after 4 days of therapy.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from he analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With Cystathionine Beta Synthase Deficient Homocystinuria (CBSDH) Pre and Post Taurine Treatment.</title>
          <description>TBARS were measured in plasma via colorimetric absorbance. TBARS are a marker of oxidative stress. They are formed as a by-product of lipid (fat) oxidation. TBARS predominantly reflect the level of malondialdehyde (MDA) a substance that is formed from the breakdown of polyunsaturated fatty acids.</description>
          <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from he analysis.</population>
          <units>nmol/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis applied.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis</non_inferiority_desc>
            <p_value>0.235</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference in Tumor Necrosis Factor Alpha (TNF-alpha) in Individuals With CBSDH Pre and Post Taurine Treatment.</title>
        <description>TNF-alpha was measured in plasma via Luminex high sensitivity assay. TNF-alpha is a signaling protein, or cytokine that promotes an inflammatory response.</description>
        <time_frame>Baseline and after 4 days of treatment.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Tumor Necrosis Factor Alpha (TNF-alpha) in Individuals With CBSDH Pre and Post Taurine Treatment.</title>
          <description>TNF-alpha was measured in plasma via Luminex high sensitivity assay. TNF-alpha is a signaling protein, or cytokine that promotes an inflammatory response.</description>
          <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.95" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis assumed.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis.</non_inferiority_desc>
            <p_value>0.701</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH Pre and Post Taurine Treatment</title>
        <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
        <time_frame>Baseline and after 4.5 days of taurine treatment</time_frame>
        <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH Pre and Post Taurine Treatment</title>
          <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
          <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.80" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.57" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis applied.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis.</non_inferiority_desc>
            <p_value>0.190</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH and Homocysteine Levels Greater Than 125 Micromole/L Pre and Post Taurine Treatment.</title>
        <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
        <time_frame>Baseline and after 4.5 days of therapy.</time_frame>
        <population>Analyzable data from all individuals with CBSDH having baseline homocysteine levels greater than 125 micromole/L who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH and Homocysteine Levels Greater Than 125 Micromole/L Pre and Post Taurine Treatment.</title>
          <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
          <population>Analyzable data from all individuals with CBSDH having baseline homocysteine levels greater than 125 micromole/L who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.10" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis applied.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis.</non_inferiority_desc>
            <p_value>0.052</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH and Pre Taurine Exposure FMD Values Less Than 10 mm Pre and Post Taurine Treatment.</title>
        <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
        <time_frame>Baseline and after 4.5 days of therapy.</time_frame>
        <population>Analyzable data from all individuals with CBSDH studied with baseline flow mediated dilation values of less than 10 mm and who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Endothelial Function (Blood Vessel Function) in Individuals With CBSDH and Pre Taurine Exposure FMD Values Less Than 10 mm Pre and Post Taurine Treatment.</title>
          <description>Endothelial function was measured by doppler brachial artery flow-mediated dilation (FMD) studies.</description>
          <population>Analyzable data from all individuals with CBSDH studied with baseline flow mediated dilation values of less than 10 mm and who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis assumed.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis.</non_inferiority_desc>
            <p_value>0.014</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Individuals With Decreased Bone Mineral Density.</title>
        <description>Bone mineral density was assessed via whole body dual energy X-ray absorptiometry (DEXA) with bone density corrected for age. The absolute DEXA value was not used for analysis, rather values below 2 standard deviations of normal were taken as evidence of osteoporosis.</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis was on all analyzable data from subjects with CBSDH who participated in the active study and data from control population as provided by DEXA report.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention</title>
            <description>Baseline value prior to taurine intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Individuals With Decreased Bone Mineral Density.</title>
          <description>Bone mineral density was assessed via whole body dual energy X-ray absorptiometry (DEXA) with bone density corrected for age. The absolute DEXA value was not used for analysis, rather values below 2 standard deviations of normal were taken as evidence of osteoporosis.</description>
          <population>Analysis was on all analyzable data from subjects with CBSDH who participated in the active study and data from control population as provided by DEXA report.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal bone mineral denisty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal bone mineral density</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With CBSDH Compare to Homocysteine Level.</title>
        <description>TBARS were measured in plasma via colorimetric absorbance. Homocysteine was measured in serum by gas chromatography/mass spectrometry (GC/MS) in a Clinical Laboratory Improvements Amendments (CLIA) approved clinical laboratory. TBARS are a marker of oxidative stress. TBARS are formed as a by-product of lipid (fat) oxidation. TBARS predominantly reflect the level of malondialdehyde (MDA) a substance that is formed from the breakdown of polyunsaturated fatty acids.</description>
        <time_frame>Baseline</time_frame>
        <population>Analyzable data from all subjects with CBSDH who completed day one of active study and normal homocysteine values provided by assaying laboratory were used for the calculations.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>Baseline value prior to taurine intervention on day two of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Thiobarbituric Acid Reactive Substances (TBARS) in Individuals With CBSDH Compare to Homocysteine Level.</title>
          <description>TBARS were measured in plasma via colorimetric absorbance. Homocysteine was measured in serum by gas chromatography/mass spectrometry (GC/MS) in a Clinical Laboratory Improvements Amendments (CLIA) approved clinical laboratory. TBARS are a marker of oxidative stress. TBARS are formed as a by-product of lipid (fat) oxidation. TBARS predominantly reflect the level of malondialdehyde (MDA) a substance that is formed from the breakdown of polyunsaturated fatty acids.</description>
          <population>Analyzable data from all subjects with CBSDH who completed day one of active study and normal homocysteine values provided by assaying laboratory were used for the calculations.</population>
          <units>micromol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TBARS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00365" spread="0.00087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homocysteine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" spread="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis assumed</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis</non_inferiority_desc>
            <p_value>.541</p_value>
            <method>Spearman's rank correlation</method>
            <other_analysis_desc>Spearman's rank correlation rho is 0.179, with p value 0.541, N is 14</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Determination of Baseline Taurine Level, Peak Taurine Level on Day One, Trough Level on Day One and Trough Level on Day Four of Taurine Treatment.</title>
        <description>Taurine was measured in plasma via liquid chromatogram(LC)-MS/MS.</description>
        <time_frame>Taurine levels were obtained prior to taurine adminstration and at , t=0.5, t=1, t=2, t=3, t=4, t=6, t=8, t=12 and 96 hours.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Determination of Baseline Taurine Level, Peak Taurine Level on Day One, Trough Level on Day One and Trough Level on Day Four of Taurine Treatment.</title>
          <description>Taurine was measured in plasma via liquid chromatogram(LC)-MS/MS.</description>
          <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
          <units>microM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak Value Day One</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="753.0" spread="240.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Value Day One 12h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Value Day Four</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference in Triglycerides in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment)</title>
        <description>Triglycerides were measured in a CLIA approved clinical laboratory.Triglycerides are a natural occurring fat. High levels over a long period of time can increase the chances for heart disease. Levels greater that 1000 mg/dl over a short period of time can increase chances of pancreatitis.</description>
        <time_frame>Baseline and after 4 days of treatment.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who were treated with taurine, this being both low dose and targeted dose of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Triglycerides in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment)</title>
          <description>Triglycerides were measured in a CLIA approved clinical laboratory.Triglycerides are a natural occurring fat. High levels over a long period of time can increase the chances for heart disease. Levels greater that 1000 mg/dl over a short period of time can increase chances of pancreatitis.</description>
          <population>Analyzable data from all individuals with CBSDH who were treated with taurine, this being both low dose and targeted dose of medication.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Taurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.7" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis assumed</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis</non_inferiority_desc>
            <p_value>0.014</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference in Triglycerides in Individuals With CBSDH Receiving Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment)</title>
        <description>Triglycerides were measured in a CLIA approved clinical laboratory. Triglycerides are a natural occurring fat, High levels over a long period of time can increase the chances for heart disease. Levels greater that 1000 mg/dl over a short period of time can increase chances of pancreatitis.</description>
        <time_frame>Baseline and after 4 days of treatment.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Triglycerides in Individuals With CBSDH Receiving Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment)</title>
          <description>Triglycerides were measured in a CLIA approved clinical laboratory. Triglycerides are a natural occurring fat, High levels over a long period of time can increase the chances for heart disease. Levels greater that 1000 mg/dl over a short period of time can increase chances of pancreatitis.</description>
          <population>Analyzable data from all individuals with CBSDH who received the target dose of taurine were used for the calculations. The two individuals treated with low dose taurine were excluded from the analysis.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis assumed</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis</non_inferiority_desc>
            <p_value>0.012</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference in Systolic Blood Pressure in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment).</title>
        <time_frame>Baseline and after 4 days of treatment.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who were treated with taurine, this being both low dose and targeted dose of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Systolic Blood Pressure in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment).</title>
          <population>Analyzable data from all individuals with CBSDH who were treated with taurine, this being both low dose and targeted dose of medication.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Taurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis applied.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis.</non_inferiority_desc>
            <p_value>0.160</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Difference in Diastolic Blood Pressure in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment).</title>
        <time_frame>Baseline and after 4 days of treatment.</time_frame>
        <population>Analyzable data from all individuals with CBSDH who were treated with taurine, this being both low dose and targeted dose of medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Taurine Intervention Group</title>
            <description>For safety reason, the first two subjects studies received low dose taurine therapy: 25 mg/kg body weight twice a day (maximum dose 1.5 grams). There after all received target dose therapy: 75 mg/kg body weight twice a day (maximum dose of 5 grams).</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Diastolic Blood Pressure in Individuals With CBSDH Receiving Both Low Dose and Target Dose Taurine Pre and Post Taurine Treatment (Safety Assessment).</title>
          <population>Analyzable data from all individuals with CBSDH who were treated with taurine, this being both low dose and targeted dose of medication.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Taurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Taurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Descriptive analysis</non_inferiority_desc>
            <p_value>0.10</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19 days (During the 5 days taurine was administered plus two weeks after taurine administration.)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Taurine Intervention</title>
          <description>Taurine Intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Johan Van Hove, Primary Investigator</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-2338</phone>
      <email>johan.vanhove@childrenscolorado.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

